-
The concept of ursodeoxycholic acid suddenly became popular, and pharmaceutical companies issued announcements in response
Time of Update: 2023-01-01
js?cdnversion='+~(-new Date()/36e5)];On December 7, the concept stock of ursodeoxycholic acid broke out across the board, with Sinotherapeutics and Gonggong Pharmaceutical gaining a 20CM price limit, and Shuangcheng Pharmaceutical and Qianhong Pharmaceutical gaining a limit.
-
Can the concept of "new crown miracle drug" ursodeoxycholic acid set off a new round of research and development?
Time of Update: 2022-12-30
On December 5, researchers at the University of Cambridge in the United Kingdom published an article in the journal Nature called "FXR inhibition may protect from. " SARS-CoV-2 infection by reducing A
-
The concept of ursodeoxycholic acid continued to skyrocket, and Xintai Pharmaceutical, Xinhua Pharmaceutical, etc. rose to the limit
Time of Update: 2022-12-29
The company's main business is the research and development, production and sales of lyophilized powder, lyophilized powder injection (including anti-tumor drugs), small volume injection (non-final sterilization), tablets, hard capsules, granules and APIs within the scope of drug production license.
-
Nature: Significant progress! Ursodeoxycholic acid, which was originally used to treat liver
Time of Update: 2022-12-30
In a new study, researchers from research institutions such as the University of Cambridge in the United Kingdom and the Charité Inky in Berlin, Germany, looked at miniature organs, donor organs, ani
-
Ursodeoxycholic acid concept stocks strengthen! Sinotherapeutical's "one" word is up and down, and many stocks such as Common Pharmaceutical have soared
Time of Update: 2022-12-29
According to the data, Gong Gong Pharmaceutical is an enterprise specializing in the research and development, production and sales of steroid hormone drug raw materials, and its main products are starting materials and intermediates required for the production of steroid drugs 。 According to the 2022 third quarter report of Mutual Pharmaceutical, the company's main revenue in the first three quarters of this year was 447 million yuan, an increase of 0.
-
J Gastroenterology: Ursodeoxycholic acid is associated with improved long-term outcomes in patients with primary sclerosing cholangitis
Time of Update: 2022-11-25
Primary sclerosing cholangitis (PSC) is a chronic cholestatic disorder of unknown etiology characterized by progressive narrowing and destruction of the bile ducts due to diffuse inflammation and fibrosis, eventually leading to cirrhosis and liver failure.
-
J Gastroenterology: Ursodeoxycholic acid may improve long-term prognosis in patients with primary sclerosing cholangitis
Time of Update: 2022-10-02
This study confirmed that UDCA use was significantly associated with improved LT-free survival in patients with PSC, suggesting that UDCA improves long-term prognosis in patients with PSC.
-
J Gastroenterology: Ursodeoxycholic acid may reduce the risk of gallstones and cholecystectomy after bariatric surgery
Time of Update: 2022-08-16
. This study demonstrates that prophylactic use of UDCA after bariatric surgery prevents gallstone formation and symptomatic GD and reduces the risk of cholecystectomy .
. This study demonstrates that prophylactic use of UDCA after bariatric surgery prevents gallstone formation and symptomatic GD and reduces the risk of cholecystectomy .
-
Ursodeoxycholic acid
Time of Update: 2022-06-08
Thin layer plate silica gel GDeveloping agent isooctane- ethyl acetate - glacial acetic acid (15:7:5)Check 10% sulfuric acid ethanol solution, bake at 105℃ until the spots are clear, observe under sunlight and ultraviolet light (365nm)2.
-
The Lancet Gastroenterology & Hepatology: Ursodeoxycholic acid can be used to prevent symptomatic gallstone disease after bariatric surgery
Time of Update: 2022-01-07
This study aims to evaluate the efficacy of ursodeoxycholic acid compared with placebo in preventing symptomatic gallstone disease after bariatric surgery .
Cholesterol prevention This is a multicenter, double-blind, randomized, placebo-controlled trial involving patients with intact gallbladder who plan to undergo laparoscopic Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy .